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Abstract
The incidence of lung cancer in Maltese males is higher than 
that in females. However trends in Maltese and other foreign 
populations indicate a substantial recent increment in the 
diagnosis of lung cancer in women. In this retrospective study 
we report the trends seen along the last decade in bronchoscopic 
findings of bronchoscopies carried out by one hospital firm in 
order to try and reflect the practices and results of this important 
endoscopic investigation on the incidence, diagnosis and 
treatment of lung malignancies in Malta. 
Introduction
In Malta, lung and prostate cancer are the most commonly 
diagnosed form of malignant tumours found in males. However, 
as opposed to prostate cancer, the prognosis for a newly 
diagnosed patient with lung cancer is alarmingly discouraging. 
Whereas even in the sixth year after diagnosis, prostate cancer 
patients have a relative survival rate of over 70%, less than 
30% of patients survive the first year of lung cancer diagnosis. 
Mortalities due to lung cancer rank foremost amongst other 
common cancers.1
Smoking is still the most common exogenous factor 
influencing the onset of lung cancer. The association between 
smoking, the numerous carcinogens found in cigarette smoke 
and lung cancer has been proven in various published studies.2-5 
However, this is not to say that smoking is the sole factor 
determining the risk of developing the disease as radiation, 
other carcinogens such as asbestos, inhaled industrial agents and 
genetic polymorphisms also have a role to play in the aetiology 
of this malignancy. The onset of lung cancer, in all its forms, 
as mediated by smoking is a complex mechanism. To date, 
among all the components of tobacco smoke, 20 carcinogens 
have been found to cause lung tumours in laboratory animals 
and humans alike.6-9 Among these components, polycyclic 
aromatic hydrocarbons and the tobacco-specific nitrosamine 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone are likely to 
play a pivotal role in lung cancer induction. This mechanism 
is also genetic in nature since it is thought that tobacco smoke 
carcinogens interact with DNA and induce genetic changes in 
the form of mutations in oncogenes and tumour suppressor 
genes.10-12
The incidence of lung cancer in Maltese males is higher 
than that in females. However, trends in Maltese and other 
foreign populations indicate a substantial recent increment in 
the diagnosis of lung cancer in women. This occurrence might 
be attributable to the increase in female smokers over the 
last decades. In 2004 a study conducted by Sant Portanier et 
al.13 indicates that the number of Maltese female smokers has 
doubled from 10.2% in 1995 to 21% in 2004 and in the 40 – 45 
year old age group females were more likely to be smokers and 
also more likely to consume more cigarettes daily than their 
male counterparts.
In addition, studies indicate that throughout the years, 
tobacco smoking patterns have altered the ranking order of the 
‘league table’ of the histopathological types of lung cancer.14-15 
This started to be observed in the 1950s when the introduction 
of filter-tip cigarettes in combination with advancements in 
diagnostic techniques led to a worldwide increase in the reported 
incidence of pulmonary adenocarcinomas. It has been suggested 
that the number of adenocarcinomas has been on the increase 
since filter-tip cigarette smoke is inhaled more deeply than other 
non-filtered cigarette smoke. Such deep inhalation transports 
tobacco-specific carcinogens further and more distally towards 
the bronchoalveolar junction where adenocarcinomas often 
arise.16 The 1950’s also saw the introduction of blended 
reconstituted tobacco. This form of tobacco releases higher 
concentrations of nitrosamines from tobacco stems as opposed 
to products made predominantly from tobacco leaves.17,18 
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Nitrosamines are known to induce lung adenocarcinomas in 
rodents when injected systemically.18
Along the years innovative bronchoscopic sampling 
procedures which allowed biopsies on tumours in small, 
distal airways, where these tumours often arise, proved to 
be a milestone in adenocarcinoma diagnosis. Bronchoscopic 
sampling is performed by one or more of three techniques; 
bronchoalveolar lavage (BAL), brush biopsies and tissue 
biopsies. Sampling methods undertaken are selected on a 
case by case basis. It is common practice to use more than one 
sampling method to safeguard accuracy and reliability and 
increase the chances of a positive diagnosis. Histological forms 
of lung cancer include squamous cell carcinoma, which is still the 
most widely diagnosed lung cancer. Adenocarcinoma and small 
cell carcinoma are also commonly diagnosed, the latter having 
a worse prognosis with a highly aggressive progression. Large 
cell carcinoma is another type of histopathological diagnosis 
of lung cancer.
Table 1: Bronchoscopies by gender and smoking status  
 
 1995-1996 Ratio 1999-2000 Ratio 2006-2007 Ratio
  (%M:%F)  (%M:%F)  (%M:%F)
Total no. of elective bronchoscopies 108  109  116 
Males (M) 92 (85.2%) 5.76 88 (80.7%) 4.18 87 (75%) 3
Females (F) 16 (14.8%)  21 (19.3%)  29 (25%)
      
Total number of smokers 43 (59.7%) 1.2 50 (52.1%) 1.1 44 (48.4%) 1.0
Males (M) 39 (90.7%) 9.75 46 (92.0%) 11.5 34 (77.3%) 3.41
Females (F) 4 (9.3%)  4 (8.0%)  10 (22.7%)
      
Total number of ex-smokers 22 (30.6%) 1.0 29 (30.2%) 1.0 28 (30.8%) 1.0
Males (M) 20 (90.9%) 9.99 27 (93.1%) 13.49 27 (96.4%) 26.78
Females (F) 2 (9.1%)  2 (6.9%)  1 (3.6%)
      
Total number of non-smokers 7 (9.7%) 0.5 17 (17.7%) 0.8 19 (20.9%) 1.0
Males (M) 5 (71.4%) 2.5 8 (47.1%) 0.89 6 (31.6%) 0.46
Females (F) 2 (28.6%)  9 (52.9%)  13 (68.4%)
Mode of presentation in Males & Females  1995/1996 1999/2000 2006/2007
resulted positive for cancer (n= 33) (%) (n=45) (%) (n=36) (%) 
Hemoptysis 9.1 28.9 19.4
Chest pain 15.2 11.1 16.7
Weight loss 15.2 20.0 13.9
Hoarseness 3.0 4.4 5.6
Pyrexia of Unknown Origin 3.0 4.4 0.0
Persistent cough 12.1 15.6 22.2
Shortness Of Breath 24.2 20.0 16.7
Unresolving pneumonia 6.1 4.4 5.6
Brain metastasis 12.1 6.7 2.8
Past history of Cancers* 0.0 4.4 8.3
Abnormal Chest X-Ray 87.9 97.8 83.3
Abnormal CT Scan 12.1 2.2 16.7
Others** 15.2 20.0 25.0
Table 2: Mode of presentation of lung tumours
[* colon, larynx and squamous cell carcinoma of the skin]
[**pleural effusion, past history of rheumatoid arthritis, past history of extrinsic allergic alveolitis, high Erythrocyte 
sedimentation rate (ESR), fainting, back pain, bone pain, lymphadenopathy, neuropathy, herpes zoster, Syndrome of 
Inappropriate ADH secretion, superior vena caval obstruction]
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In this paper we report the trends seen along the last decade 
in bronchoscopic findings of bronchoscopies carried out by one 
hospital firm in order to try and reflect the practices and results 
of this important endoscopic investigation on the incidence, 
diagnosis and treatment of lung malignancies in Malta. 
Methods
This retrospective study aimed to compare the indications, 
findings and sampling methods used in diagnostic fibreoptic 
bronchoscopies carried out at three different time-points spaced 
over a decade.
The reports of the diagnostic bronchoscopies carried out by 
the firm headed by a single respiratory physician [SM] in the 
periods 1995/96, 1999/2000 and 2006/7 were utilised. The 
records audited were sampled from the middle of the year till 120 
bronchoscopies were reached at each time-point. Therapeutic 
bronchoscopies carried out mostly in intensive care setting were 
then excluded as these were beyond the scope of this study. As 
these bronchoscopies were decided on and carried out by the 
same respiratory physician, the policies for choice of patients 
requiring bronchoscopy and the protocol and sampling methods 
used were all similar across the decade in question. The analysis 
carried out on the data involved:
a] demography of the patients bronchoscoped including their 
smoking status,
b] indications for the fibreoptic bronchoscopy,
c] diagnosis of bronchial malignancy if any and any gender-
related or smoking-related differences which might be 
present,
d] the histological types of malignancies diagnosed, and
e] the sampling methods used and which were most sensitive 
and useful in detecting a malignant lesion.
As the sampling periods were irregular and the aim of the 
study was comparative, statistical analysis was carried out 
mostly on percentage values; Fisher’s exact test was used.
Results
The numbers of patients studied in this retrospective study 
were relatively small and thus there was not enough power for 
statistical significance to be reached in any of the analysis carried 
out. However, some clear trends were apparent and we thought 
that these should lead to interesting speculative discussion.
Figure 1: Trends between genders, incidence of elective 
bronchoscopies and incidence of smoking status
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Figure 2: Number of Malignancies detected by Gender 
and Smoking Status
Pa
tie
nt
s 
(%
)
90
80
70
60
50
40
30
20
10
0
1995-1996
1999-2000
2006-2007
Ma
le s
mo
ker
s
Ma
le e
x-s
mo
ker
s
Fe
ma
le e
x-s
mo
ker
s
Ma
le n
on
 sm
ok
ers
Fe
ma
le n
on
 sm
ok
ers
Fe
ma
le s
mo
ker
s
Figure 3: Bronchoscopies with a diagnosis 
of malignancy, by period and gender
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Demography
The numbers of elective bronchoscopies carried out 
in the three sampled time-periods were: 1995/96: 108 
bronchoscopies; 1999/2000: 109 bronchoscopies and 2006/7: 
116 bronchoscopies respectively. Table 1 and Figure 1  show the 
various subsets of patients undergoing these bronchoscopies as 
subdivided into gender and smoking status for each gender i.e. 
current smokers, ex-smokers and non-smokers, for each period 
studied. The mean ages were: 61.8 yrs [range 19 – 94 yrs] in 
1995/96, 62.4yrs [range 11 – 86 yrs] in 1999/2000 and 63.3yrs 
[range 21 – 91yrs] in 2006/7. One can note that:
a] the ratio of male to female patients undergoing diagnostic 
bronchoscopies is decreasing from 5.76 in 1995/96 to 3 in 
2006/7,
b] a similar trend is also seen when one compares male and 
female smokers undergoing bronchoscopies: whereas the 
proportion of male patients undergoing bronchoscopies 
who were still current smokers has remained quite stable 
along the years studied, the proportion of female smokers 
endoscoped rose from 9.5% in 1995/96 to 22.7% in 2006/7, 
and
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c] this increase is also seen in female non-smokers [28.6% 
in 1995/6 vs 68.4% in 2006/7]. Although this reflects 
the general increase in the total number of non-smokers 
studied, the rise in females is greater and is more 
impressive because in the case of the males there has been 
a sustained decrease in their need for a bronchoscopy. No 
such changes are seen in female ex-smokers, though here 
the numbers are very small.
Mode of presentation
Table 2 shows the various indications for diagnostic 
fibreoptic bronchoscopies. These figures show that the 
commonest indication for bronchoscopy along the decade 
studied has remained that of an abnormal chest X-ray. However, 
haemoptysis and persistent cough seem to have become even 
more common reasons for referral. These three commonest 
reasons for referral were all much more common in smokers 
when compared to ex-smokers and even more so to non-
smokers.
Bronchial malignancy diagnosed 
Around a third [34.2%] of patients who were bronchoscoped 
in all the three time-periods studied ended up with a diagnosis 
of a malignant bronchial lesion:
• in 1995/96, 33 out of 108 bronchoscopies were positive for 
malignancy,
• in 1999/2000, 45 out of 109 bronchoscopies were positive 
for malignancy, and
• in 2006/7, 36 out of 116 bronchoscopies were positive for 
malignancy.
These proportions of positive results for malignancy show a 
good degree of consistency and have not increased or decreased 
substantially over the decade studied.
When these figures were further subdivided into gender-
related percentages [Figure 2] one could see that there was an 
increasing trend in bronchial malignancies in male smokers 
and a decrease in male ex-smokers. In the female subset 
there was also an increasing tendency in female non-smokers 
being diagnosed with a pulmonary malignancy through these 
bronchoscopies and a subtle decrease in the percentage of female 
smokers with such a diagnosis. However, one must remember 
that the number of female smokers increased across the studied 
time-period and this could explain this relative percentage 
decrease.
Figure 3 shows that over the studied decade the overall 
percentage of female patients undergoing bronchoscopy and 
ending up with a diagnosis of bronchial malignancy compared 
to the total number of patients at the three specific time-points 
Total 1995/ 1996 +VE % 1999/2000 +VE % 2006/2007 +VE %
Lavage 31 23 74.2 44 29 65.9 35 19 54.3
Brush 32 29 90.6 43 41 95.3 34 29 85.3
Biopsy 14 11 78.6 10 9 90.0 10 7 70.0
Table 4.  The three main bronchial investigative sampling methods used and their yield
Males
Histological Types %  % %
 of total   of total  of total
Squamous cell carcinoma 36.7 51.3 44.8
Small cell carcinoma 30 15.3 10.3
Adenocarcinoma 13.3 15.3 31
Undifferentiated carcinoma 13.3 7.7 10.3
Large cell carcinoma 6.7 7.7 0
Lymphoma 0 2.6 3.4
 
Females
Histological Types % of  % of % of
 total   total  total
Squamous cell carcinoma 33.3 66.7 42.9
Small cell carcinoma 0 16.7 28.6
Adenocarcinoma 33.3 0 14.3
Undifferentiated carcinoma 0 16.7 14.3
Large cell carcinoma 33.3 0 0
Lymphoma 0 0 0
Table 3.  Histological types of lung tumours
Figure 4: Trends in histological results throughout the 
three different time points
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analysed has increased markedly from 14.8%, in 1995/96, to 
19.3%, in 1999/2000, and to 25.0% in 2006/7.
Histological types of diagnosed malignancies 
Figure 4 shows that whereas squamous cell carcinoma 
remained the most common histological type of bronchial 
malignancy, there was an impressive increase in the rate of 
increase of the incidence of adenocarcinomas and a decrease in 
small cell and large cell carcinomas along the years. However 
table 3 reveals that it is in males that the greatest increase in 
adenocarcinoma has occurred while in females there was an 
increase in the number of small cell carcinomas diagnosed. 
Although the numbers were small one could also see that 
some pulmonary lymphomas being diagnosed during these 
bronchoscopies.
Sampling methods
In table 4 one can see that bronchial brushings have 
remained the most reliable and sensitive mode of positive 
sampling for bronchial malignancies. Bronchial lavage has 
shown some loss of sensitivity while bronchial biopsies, which 
are least utilised, have remained stable in the rates of confirming 
a positive diagnosis of pulmonary malignant lesions.
Discussion
This comparative retrospective study has showed some 
interesting trends, between the three chosen time-points 
spanning a decade, in the demography of patients undergoing 
diagnostic fibreoptic bronchoscopies, in the indication for the 
bronchoscopy, in the differing rates of diagnosis of bronchial 
malignancies among the different patient groups, in the 
histological types of tumours seen and in the pick-up rates of 
the various sampling modalities utilised.
The general trend of the results shows an increase in the 
prevalence of bronchial malignant tumours in female patients 
and this is also reflected in the changes seen in the male to 
female ratio of patients undergoing this type of endoscopy. 
One could note that between 1995/6 and 2006/7 the female 
proportion undergoing bronchoscopies rose from 14.8% to 
25%. A surprising finding was that this increase was not found 
uniquely in female smokers but also in non-smokers. In the 
male patients undergoing bronchoscopies the numbers have 
remained quite stable over the time-span studied and this status 
quo was noted in all subsets of patients, whether they were 
smokers, ex-smokers or non-smokers.
This increase of  female non-smokers requiring 
bronchoscopies, which runs parallel with that seen in the 
case of their smoking counterparts, is further echoed in the 
finding of an increase in bronchial malignancies diagnosed 
in these non-smokers along the decade. This even surpasses 
the rate seen in the female smoking group were there was an 
actual decrease in bronchial carcinomas. This finding of female 
non-smokers developing more bronchial malignancies when 
compared to their male counterparts along the years has been 
reported elsewhere.19,20 In fact whereas it is estimated that 85% 
of males with lung cancer are smokers, in females this figure is 
only around 47% worldwide21 and 70% in Europe.22 Although 
tobacco is still the commonest cause of lung cancer in both sexes 
one cannot ignore this apparent increase in risk for this type of 
cancer in non-smoking females. One could question whether all 
female patients were truthful about their smoking status but one 
must also speculate that they might be more sensitive to inhaled 
carcinogens such as those found in environmental tobacco 
smoke.23-27 It has been suggested that females might be more 
susceptible to tobacco-smoke induced DNA damage and that 
they have a lower ability to repair such damage. In fact mutations 
to this DNA such as the K-Ras mutations are commoner in 
female than male smokers and have also been detected in non-
smoking females.28-30 One must remember that on the whole 
female smokers still smoke less than men so it does seem that 
they are more prone to tobacco–induced carcinogenesis. This 
seems to reflect the increased preponderance in women to 
develop liver cirrhosis when they abuse alcohol when compared 
to men.31
The percentage of all the patients undergoing bronchoscopies 
and ending up with a diagnosis of bronchial malignancies has 
remained quite stable along the years – at around 35%. However, 
as discussed above there are major differences related to gender. 
Whereas in 1995/6 the ratio of female to male lung cancer victims 
was 1:9 [14.8%], this increased to 1:7 [19.3%] in 1999/2000 and 
1:4 [25%] in 2006/7. These figures compare quite well to the 
national female/male ratio in the incidence of lung cancer in the 
National cancer registry [14/111 – 12.6% in 1996; 23/121 – 19% 
in 2000; 27/115 – 23.5% in 2006]1 and enhance the reliability of 
our results. From these figures one can see that in these 3 time-
points the national overall figures for lung cancer has remained 
relatively stable 125 [1995], 144 [2000] and 142 [2006]1 As in 
the case of other European countries this is due to an increase 
in lung malignancies in females and a decrease in the males at 
the same time.32 A local study in 1987 had noted that only 9% 
of lung cancers in Malta were found in females,33 thus showing 
that this incidence increased by almost three times over twenty 
years. This increase in females with lung cancer is becoming 
a more common cause of death secondary to malignancy and 
is catching up to the death rate secondary to breast cancer. In 
France, in 1985, cancer of the lung was the sixth highest cause 
of cancer-related deaths but in 1995 it went up to the third 
commonest.34,35 
These pulmonary malignancies have also shown that along 
the years all adenocarcinomas are showing a steep rise in 
prevalence. In Europe, adenocarcinoma is the most common 
histological type of lung cancer in females while squamous cell 
carcinoma is still the commonest in males but, even in this sex, 
adenocarcinoma is on the increase.32,36,37 One hypothesis for this 
reason is that adenocarcinomas, previously more common in 
non-smokers, is that higher consumption of low-tar cigarettes 
with better filters lead to deeper inhalations by smokers during 
smoking this type of cigarette. This is thought to lead to more 
peripheral delivery of the smoke where adenocarcinomas are 
more likely to develop.16
During our bronchoscopies we employed various sampling 
modalities according to macroscopic findings seen. In central 
airway lesions all three i.e. bronchial lavage, brushings and 
biopsies were utilised while in more peripheral lesions biopsies 
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were less used than the other two methods of sampling. The 
pick-up rate, as in the past,38 turned out to be that acquired 
by bronchial brushings which are sometimes taken ‘blindly’ or 
under fluoroscopy for peripheral lesions and sent for cytology. 
Lavage seems to be less sensitive, possibly because of the dilution 
factor on scanty numbers of collected cells from bronchial 
lining and lesions, while biopsies might suffer from sampling 
of necrotic areas seen on the tumour surfaces apart from the 
obvious small size of the sampling biopsy forceps.
 In conclusion we have seen that over the past decade the 
trends in bronchoscopies and their findings have shown an 
increase in female patients undergoing bronchoscopies, an 
increase in the general proportion of females being diagnosed 
with lung malignancies especially so in female non-smokers. 
There has also been an impressive increase in adenocarcinomas 
of the lung which like other pulmonary malignancies in our 
series, were mostly picked up by bronchial brushings carried 
out during bronchoscopy.
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